Needham Maintains I-Mab - ADR (IMAB) Buy Recommendation

Fintel reports that on September 25, 2023, Needham maintained coverage of I-Mab - ADR (NASDAQ:IMAB) with a Buy recommendation.

Analyst Price Forecast Suggests 2,352.51% Upside

As of August 31, 2023, the average one-year price target for I-Mab - ADR is 29.43. The forecasts range from a low of 3.84 to a high of $106.05. The average price target represents an increase of 2,352.51% from its latest reported closing price of 1.20.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for I-Mab - ADR is 69MM. The projected annual non-GAAP EPS is -1.35.

What is the Fund Sentiment?

There are 93 funds or institutions reporting positions in I-Mab - ADR. This is a decrease of 9 owner(s) or 8.82% in the last quarter. Average portfolio weight of all funds dedicated to IMAB is 0.04%, a decrease of 34.57%. Total shares owned by institutions decreased in the last three months by 9.34% to 19,447K shares. IMAB / I-Mab - ADR Put/Call Ratios The put/call ratio of IMAB is 0.27, indicating a bullish outlook.

What are Other Shareholders Doing?

IMAB / I-Mab - ADR Shares Held by Institutions

Hillhouse Capital Advisors holds 6,909K shares representing 8.32% ownership of the company. In it's prior filing, the firm reported owning 6,954K shares, representing a decrease of 0.65%. The firm increased its portfolio allocation in IMAB by 3.12% over the last quarter.

Artal Group holds 850K shares representing 1.02% ownership of the company. No change in the last quarter.

VEIEX - Vanguard Emerging Markets Stock Index Fund Investor Shares holds 754K shares representing 0.91% ownership of the company. No change in the last quarter.

VGTSX - Vanguard Total International Stock Index Fund Investor Shares holds 720K shares representing 0.87% ownership of the company. No change in the last quarter.

Bank Of America holds 678K shares representing 0.82% ownership of the company. In it's prior filing, the firm reported owning 681K shares, representing a decrease of 0.46%. The firm decreased its portfolio allocation in IMAB by 12.21% over the last quarter.

I-Mab Background Information
(This description is provided by the company.)

I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.